├── data ├── VaC_LSHTM_Covid_vaccine_trials_11November2020.xlsx └── WHO-VaccineCandidates_2020-11-12.csv └── README.md /data/VaC_LSHTM_Covid_vaccine_trials_11November2020.xlsx: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/dw-data/covid19-vaccine-tracker/HEAD/data/VaC_LSHTM_Covid_vaccine_trials_11November2020.xlsx -------------------------------------------------------------------------------- /README.md: -------------------------------------------------------------------------------- 1 | # COVID-19 vaccine tracker 2 | 3 | Idea: [Eva Lopez](https://twitter.com/evopez) 4 | 5 | Research, data analysis and visualization, writing: [Gianna-Carina Grün](https://twitter.com/giannagruen) 6 | 7 | Editing: Fabian Schmidt, [Zulfikar Abbany](https://twitter.com/zulfikarabbany) 8 | 9 | You can read the story in [English](https://p.dw.com/p/3lUln), [Deutsch](https://p.dw.com/p/3lQ2q), [Español](https://p.dw.com/p/3lVQA), [Português do Brasil](https://p.dw.com/p/3lWb1), [Indonesia](https://p.dw.com/p/3lY9G) 10 | 11 | 12 | ## Data sources 13 | 14 | This analysis is based on two different data sources that are structured differently and thus used to answer different questions as part of this analysis. 15 | 16 | In the dataset provided by the [**WHO**](https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines), each row corresponds to one developer and their vaccine candidate. In this analysis, this dataset is used to 17 | * show how many vaccine candidates are in which phase 18 | * classify the vaccine candidates according to their type, and subsequently also phase 19 | 20 | In the "Clinical trials database" compiled by the [**London School of Hygiene and Tropical Medicine (LSHTM)**](https://vac-lshtm.shinyapps.io/ncov_vaccine_landscape/), each row corresponds to a registered clinical trial -- accordingly, a developer team testing their vaccine in multiple phases in parallel will see multiple entries in this dataset. In this analysis, this dataset is used to 21 | * show trial sizes by phase by company 22 | * provide estimates (min, max, median) of the clinical phases 23 | 24 | 25 | ## Comparisons with other vaccine trackers 26 | 27 | Other media companies too have implemented vaccine development trackers ([NYTimes](https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html), [Guardian](https://www.theguardian.com/world/ng-interactive/2020/nov/10/covid-vaccine-tracker-when-will-a-coronavirus-vaccine-be-ready), [Milken Institute](https://www.covid-19vaccinetracker.org/), [Zeit Online](https://www.zeit.de/wissen/gesundheit/2020-08/impfstoffentwicklung-corona-impfstoff-klinische-phasen-forschung)). 28 | 29 | You will see that numbers differ, based on 30 | * the **sources** used and 31 | * whether **trials or vaccine candidates** are counted and 32 | * based on the **distinction between "in approval" and "approved"**; we chose to not show the process, but only signify a vaccine as "approved" once the major authorities have done so 33 | 34 | 35 | ## Definitions 36 | 37 | ### Assignment of clinical phases 38 | 39 | There are five phases of clinical trials: Phase I, Phase I/II, Phase II, Phase II/III, Phase III. 40 | 41 | If a vaccine is in a dual phase like `Phase I/II` or in `Phase II/III` it is tested there simultaneously, but for analysis assigned to the higher phase: a vaccine candidate in `Phase I/II`is assigned to `Phase II`, whereas a vaccine candidate tested in `Phase II/III` it is assigned to `Phase III`. 42 | 43 | Beyond these dual phases, vaccine candidates can be in different clinical trial phases at the same time (e.g. `Phase I` and `Phase III`) with different trial parameters (age, pre-existing conditions). If that is the case for a candidate, it is shown in both phases. 44 | 45 | ### Approval 46 | 47 | Each country has their own national regulatory authorities (NRA) responsible for approving for new drugs in their country. There are several NRAs that are particularly relevant, among them the US-American [FDA](https://www.fda.gov/vaccines-blood-biologics/industry-biologics/coronavirus-covid-19-cber-regulated-biologics) and the European [EMA](https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines-covid-19). We signify a COVID-19 vaccine as approved if one of these bodies approves a vaccine. 48 | 49 | We will also classify a vaccine as approved if one of these two bodies greenlights a new vaccine on their ["emergency use listing"](https://www.who.int/news-room/q-a-detail/coronavirus-disease-use-of-emergency-use-listing-procedure-forvaccines-against-covid-19), or if the [WHO](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice) does so. 50 | 51 | | Vaccine Candidate | Approved by | on | notes | 52 | |------------------|------|-------------|--------------------| 53 | | BioNTech-Pfizer | FDA | 2020-12-12 | for emergency use | 54 | | BioNTech-Pfizer | EMA | subsequently | for emergency use | 55 | | Moderna | FDA | 2020-12-19 | for emergency use | 56 | | Moderna | EMA | subsequently | for emergency use | 57 | | Oxford/AstraZeneca | EMA | 2021-01-29 | for emergency use | 58 | | Janssen | EMA | 2021-03-11 | for emergency use | 59 | | Sinopharm | WHO | 2021-06-03 | for emergency use | 60 | | Sinovac | WHO | 2021-06-03 | for emergency use | 61 | 62 | 63 | ### Time ranges 64 | 65 | For the duration of clinical trial phases, we rely on the LSHTM data publishing the estimates provided by research groups. They proved a `start date` for their clinical trials and a `primary completion date`. 66 | 67 | The `primary completion date` is [defined](https://prsinfo.clinicaltrials.gov/definitions.html#PrimaryCompletionDate) as *"The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "estimated" primary completion date is the date that the researchers think will be the primary completion date for the study."* 68 | 69 | 70 | ## Data processing 71 | 72 | Datasets were downloaded from the above mentioned sources. The data provided by LSHTM did not undergo any form of pre-processesing as it already came in a machine-readable format. 73 | 74 | As the data by **WHO** is published in form of a pdf, the dowloaded file undergoes a couple of pre-processing steps before analysis can start. 75 | 76 | First, the pdf was converted into a machine-readable format using the software Abbyy Fine Reader and subsequently cleaned manually. 77 | 78 | The datasets consists of two parts: the first table is labelled `xx candidate vaccines in clinical evaluation` , whereas `xx` corresponds to the number of rows in that table. It's followed by the second table `yy candidate vaccines in preclinical evaluation` that has a slightly different columns compared to the first one. 79 | 80 | In combining both datasets, we established the one for analysis that holds the following columns 81 | 82 | | column | description | 83 | |----------------|------------------------| 84 | | COVID-19 Vaccine developer/manufacturer | Name of developer/manufacturer or team of developers/manufacturers, separated by `/` | 85 | | Vaccine platform | Type of vaccine\* | 86 | | Preclinical| `preclinical` if True, else no value | 87 | | Phase 1 | if there's a trial in this phase, cell holds one or multiple trial numbers | 88 | | Phase 1/2 | if there's a trial in this phase, cell holds one or multiple trial numbers | 89 | | Phase 2 | if there's a trial in this phase, cell holds one or multiple trial numbers | 90 | | Phase 3 | if there's a trial in this phase, cell holds one or multiple trial numbers | 91 | 92 | \* For entries in the column `Vaccine platforms` we noticed different spellings of the same type, for example `Protein subunit, Protein Subunit or Protein Sub-unit` or `Non-replicating viral vector or non replicating viral vector`, which were unified to be spelled the same way before exporting the dataset for analysis. 93 | 94 | -------------------------------------------------------------------------------- /data/WHO-VaccineCandidates_2020-11-12.csv: -------------------------------------------------------------------------------- 1 | COVID-19 Vaccine developer/manufacturer;Vaccine platform;Preclinical;Phase 1;Phase 1/2;Phase 2;Phase 3 2 | Sinovac;Inactivated;;;x;;x 3 | Wuhan Institute of Biological Products/Sinopharm;Inactivated;;;x;;x 4 | Beijing Institute of Biological Products/Sinopharm;Inactivated;;;x;;x 5 | Bharat Biotech;Inactivated;;;x;;x 6 | University of Oxford/AstraZeneca;Non-Replicating Viral Vector;;;x;x;x 7 | CanSino Biological Inc./Beijing Institute of Biotechnology;Non-Replicating Viral Vector;;x;;x;x 8 | Gamaleya Research Institute;Non-Replicating Viral Vector;;;x;x;x 9 | Janssen Pharmaceutical Companies;Non-Replicating Viral Vector;;;x;x;x 10 | Novavax;Protein Subunit;;;x;x;x 11 | Moderna/NIAID;RNA;;x;;x;x 12 | BioNTech/Fosun Pharma/Pfizer;RNA;;x;x;;x 13 | Beijing Wantai Biological Pharmacy/ Xiamen University;Replicating Viral Vector;;x;;x; 14 | Anhui Zhifei Longcom Biopharmaceutical/lnstitute of Microbiology, Chinese Academy of Sciences;Protein Subunit;;x;x;x; 15 | Curevac;RNA;;x;;x; 16 | Institute of Medical Biology, Chinese Academy of Medical Sciences;Inactivated;;x;x;; 17 | Research Institute for Biological Safety Problems, Rep of Kazakhstan;Inactivated;;;x;; 18 | Beijing Minhai Biotechnology Co., Ltd.;Inactivated;;x;x;; 19 | Inovio Pharmaceuticals/ International Vaccine Institute;DNA;;;x;; 20 | Osaka University/ AnGes/Takara Bio;DNA;;;x;; 21 | Cadila Healthcare Limited;DNA;;;x;; 22 | Genexine Consortium;DNA;;;x;; 23 | Kentucky Bioprocessing, Inc;Protein Subunit;;;x;; 24 | Sanofi Pasteur/GSK;Protein Subunit;;;x;; 25 | Biological E Ltd;Protein Subunit;;;x;; 26 | Israel Institute for Biological Research;Replicating Viral Vector;;;x;; 27 | Arcturus/Duke-NUS;RNA;;;x;; 28 | SpyBiotech/Serum Institute of India;VLP;;;x;; 29 | Symvivo;DNA;;x;;; 30 | ImmunityBio, Inc. & NantKwest Inc.;Non-Replicating Viral Vector;;x;;; 31 | ReiThera/LEUKOCARE/Univercells;Non-Replicating Viral Vector;;x;;; 32 | CanSino Biological Inc/lnstitute of Biotechnology, Academy of Military Medical Sciences, PLA of China;Non-Replicating Viral Vector;;x;;; 33 | Vaxart;Non-Replicating Viral Vector;;x;;; 34 | Ludwig-Maximilians - University of Munich;Non-Replicating Viral Vector;;x;;; 35 | Clover Biopharmaceuticals Inc./GSK/Dynavax;Protein Subunit;;x;;; 36 | Vaxine Pty Ltd/Medytox;Protein Subunit;;x;;; 37 | University of Queensland/CSL/Seqirus;Protein Subunit;;x;;; 38 | Medigen Vaccine Biologies Corporation/NIAID/Dynavax;Protein Subunit;;x;;; 39 | Instituto Finlay de Vacunas, Cuba;Protein Subunit;;x;;; 40 | Instituto Finlay de Vacunas, Cuba;Protein Subunit;;x;;; 41 | FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo;Protein Subunit;;x;;; 42 | West China Hospital, Sichuan University;Protein Subunit;;x;;; 43 | University Hospital Tuebingen;Protein Subunit;;x;;; 44 | COVAXX / United Biomedical Inc. Asia;Protein Subunit;;x;;; 45 | Merck Sharp & Dohme/IAVI;Replicating Viral Vector;;x;;; 46 | Institute Pasteur/Themis/Univ. of Pittsburg CVR/Merck Sharp & Dohme;Replicating Viral Vector;;x;;; 47 | Imperial College London;RNA;;x;;; 48 | People's Liberation Army (PLA) Academy of Military Sciences/Walvax Biotech.;RNA;;x;;; 49 | Medicago Inc.;VLP;;x;;; 50 | Biosun Pharmed;DNA;x;;;; 51 | Globe Biotech Limited, Bangladesh;DNA;x;;;; 52 | National institute of Chemistry, Slovenia;DNA;x;;;; 53 | DIOSynVax Ltd / University of Cambridge;DNA;x;;;; 54 | Ege University;DNA;x;;;; 55 | Scancell/University of Nottingham/ Nottingham Trent University;DNA;x;;;; 56 | National Research Centre, Egypt;DNA;x;;;; 57 | Karolinska Institute/ Cobra Biologies (OPENCORONA Project);DNA;x;;;; 58 | Chula Vaccine Research Center;DNA;x;;;; 59 | Takis/Applied DNA Sciences/Evvivax;DNA;x;;;; 60 | Immunomic Therapeutics, Inc./EpiVax, Inc./PharmaJet;DNA;x;;;; 61 | BioNet Asia;DNA;x;;;; 62 | Mediphage Bioceuticals/University of Waterloo;DNA;x;;;; 63 | Entos Pharmaceuticals;DNA;x;;;; 64 | Shifa Pharmed;Inactivated;x;;;; 65 | Milad Pharmaceutics Co.;Inactivated;x;;;; 66 | Zista Kian Azma Co.;Inactivated;x;;;; 67 | Kocak Farma Mac ve Kimya San. A.S.;Inactivated;x;;;; 68 | "Institute of Vaccines and Medical Biologicals (IVAC; Vietnam) / Dynavax /PATH";Inactivated;x;;;; 69 | "Government Pharmaceutical Organization (GPO; Thailand) / Dynavax / PATH";Inactivated;x;;;; 70 | Institute Butantan (Brazil) / Dynavax / PATH;Inactivated;x;;;; 71 | KM Biologies;Inactivated;x;;;; 72 | Selcuk University;Inactivated;x;;;; 73 | Erciyes University;Inactivated;x;;;; 74 | National Research Centre, Egypt;Inactivated;x;;;; 75 | Osaka University/ BIKEN/ NIBIOHN;Inactivated;x;;;; 76 | Sinovac/Dynavax;Inactivated;x;;;; 77 | Valneva/Dynavax;Inactivated;x;;;; 78 | Mehmet Ali Aydinlar University / Acibadem Labmed Health Services A.S.;Live Attenuated Virus;x;;;; 79 | Codagenix/Serum Institute of India;Live Attenuated Virus;x;;;; 80 | Indian Immunologicals Ltd/Griffith University;Live Attenuated Virus;x;;;; 81 | University of Helsinki & University of Eastern Finland;Non-Replicating Viral Vector;x;;;; 82 | Globe Biotech Limited, Bangladesh;Non-Replicating Viral Vector;x;;;; 83 | ID Pharma;Non-Replicating Viral Vector;x;;;; 84 | Ankara University;Non-Replicating Viral Vector;x;;;; 85 | Massachusetts Eye and Ear/Massachusetts General Hospital/AveXis;Non-Replicating Viral Vector;x;;;; 86 | GeoVax/BravoVax;Non-Replicating Viral Vector;x;;;; 87 | DZIF - German Center for Infection Research/IDT Biologika GmbH;Non-Replicating Viral Vector;x;;;; 88 | IDIBAPS-Hospital Clinic, Spain;Non-Replicating Viral Vector;x;;;; 89 | Altimmune;Non-Replicating Viral Vector;x;;;; 90 | Erciyes University;Non-Replicating Viral Vector;x;;;; 91 | Greffex;Non-Replicating Viral Vector;x;;;; 92 | Stabilitech Biopharma Ltd;Non-Replicating Viral Vector;x;;;; 93 | Valo Therapeutics Ltd;Non-Replicating Viral Vector;x;;;; 94 | Vaxart;Non-Replicating Viral Vector;x;;;; 95 | Centro Nacional Biotecnologfa (CNB-CSIC), Spain;Non-Replicating Viral Vector;x;;;; 96 | University of Georgia/University of Iowa;Non-Replicating Viral Vector;x;;;; 97 | Bharat Biotech/Thomas Jefferson University;Non-Replicating Viral Vector;x;;;; 98 | National Research Centre, Egypt;Non-Replicating Viral Vector;x;;;; 99 | Icahn School of Medicine at Mount Sinai;Non-Replicating Viral Vector;x;;;; 100 | Iran;Protein Subunit;x;;;; 101 | Tampere University;Protein Subunit;x;;;; 102 | Ohio State University / Kazakh National Agrarian University;Protein Subunit;x;;;; 103 | Kazakh National Agrarian University;Protein Subunit;x;;;; 104 | Neo7Logic;Protein Subunit;x;;;; 105 | Kazakh National Agrarian University, Kazakhstan / National Scientific Center for Especially Dangerous Infections;Protein Subunit;x;;;; 106 | Max-Planck-lnstitute of Colloids and Interfaces;Protein Subunit;x;;;; 107 | Farmacologicos Veterinarios SAC (FARVET SAC) / Universidad Peruana Cayetano Heredia (UPCH);Protein Subunit;x;;;; 108 | Research Institute for Biological Safety Problems, Rep of Kazakhstan;Protein Subunit;x;;;; 109 | Mynvax;Protein Subunit;x;;;; 110 | Izmir Biomedicine and Genome Center;Protein Subunit;x;;;; 111 | Bogazici University;Protein Subunit;x;;;; 112 | University of Virginia;Protein Subunit;x;;;; 113 | Helix Biogen Consult, Ogbomoso & Trinity Immonoefficient Laboratory, Ogbomoso, Oyo State, Nigeria.;Protein Subunit;x;;;; 114 | National Research Centre, Egypt;Protein Subunit;x;;;; 115 | University of San Martin and CONICET, Argentina;Protein Subunit;x;;;; 116 | Chulalongkorn University/GPO, Thailand;Protein Subunit;x;;;; 117 | AdaptVac (PREVENT-nCoV consortium);Protein Subunit;x;;;; 118 | ExpreS2ion;Protein Subunit;x;;;; 119 | IMVInc;Protein Subunit;x;;;; 120 | WRAIR/USAMRIID;Protein Subunit;x;;;; 121 | National Institute of Infectious Disease, Japan/Shionogi/UMN Pharma;Protein Subunit;x;;;; 122 | Osaka University/ BIKEN/ National Institutes of Biomedical Innovation, Japan;Protein Subunit;x;;;; 123 | Univ. of Pittsburgh;Protein Subunit;x;;;; 124 | Vaxil Bio;Protein Subunit;x;;;; 125 | Flow Pharma Inc;Protein Subunit;x;;;; 126 | AJ Vaccines;Protein Subunit;x;;;; 127 | Generex/EpiVax;Protein Subunit;x;;;; 128 | EpiVax/Univ. of Georgia;Protein Subunit;x;;;; 129 | EpiVax;Protein Subunit;x;;;; 130 | Heat Biologics/Univ. Of Miami;Protein Subunit;x;;;; 131 | FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo;Protein Subunit;x;;;; 132 | Baylor College of Medicine;Protein Subunit;x;;;; 133 | iBio/CC-Pharming;Protein Subunit;x;;;; 134 | Saint-Petersburg scientific research institute of vaccines and serums;Protein Subunit;x;;;; 135 | Innovax/Xiamen Univ./GSK;Protein Subunit;x;;;; 136 | VIDO-InterVac, University of Saskatchewan;Protein Subunit;x;;;; 137 | OncoGen;Protein Subunit;x;;;; 138 | MIGAL Galilee Research Institute;Protein Subunit;x;;;; 139 | LakePharma, Inc.;Protein Subunit;x;;;; 140 | Baiya Phytopharm/ Chula Vaccine Research Center;Protein Subunit;x;;;; 141 | Quadram Institute Biosciences;Protein Subunit;x;;;; 142 | BiOMViS Srl/Univ. of Trento;Protein Subunit;x;;;; 143 | Lomonosov Moscow State University;Protein Subunit;x;;;; 144 | University of Alberta;Protein Subunit;x;;;; 145 | AnyGo Technology;Protein Subunit;x;;;; 146 | Yisheng Biopharma;Protein Subunit;x;;;; 147 | Vabiotech;Protein Subunit;x;;;; 148 | Applied Biotechnology Institute, Inc.;Protein Subunit;x;;;; 149 | Axon Neuroscience SE;Protein Subunit;x;;;; 150 | MOGAM Institute for Biomedical Research, GC Pharma;Protein Subunit;x;;;; 151 | Neovii/Tel Aviv University;Protein Subunit;x;;;; 152 | Intravacc/Epivax;Protein Subunit;x;;;; 153 | Intravacc/Epivax;Protein Subunit;x;;;; 154 | ImmunoPrecise/LiteVax BV;Protein Subunit;x;;;; 155 | Farmacologicos Veterinarios SAC (FARVET SAC) / Universidad Peruana Cayetano Heredia (UPCH);Replicating Bacteria Vector;x;;;; 156 | Farmacologicos Veterinarios SAC (FARVET SAC) / Universidad Peruana Cayetano Heredia (UPCH);Replicating Viral Vector;x;;;; 157 | KU Leuven;Replicating Viral Vector;x;;;; 158 | Cadila Healthcare Limited;Replicating Viral Vector;x;;;; 159 | FBRI SRCVB VECTOR, Rospotrebnadzor, Koltsovo;Replicating Viral Vector;x;;;; 160 | DZIF - German Center for Infection Research/CanVirex AG;Replicating Viral Vector;x;;;; 161 | Tonix Pharma/Southern Research;Replicating Viral Vector;x;;;; 162 | BiOCADand IEM;Replicating Viral Vector;x;;;; 163 | FBRI SRCVB VECTOR, Rospotrebnadzor, Koltsovo;Replicating Viral Vector;x;;;; 164 | Fundacao Oswaldo Cruz and Instituto Buntantan;Replicating Viral Vector;x;;;; 165 | University of Hong Kong;Replicating Viral Vector;x;;;; 166 | University of Manitoba;Replicating Viral Vector;x;;;; 167 | University of Western Ontario;Replicating Viral Vector;x;;;; 168 | Aurobindo;Replicating Viral Vector;x;;;; 169 | FBRI SRCVB VECTOR, Rospotrebnadzor, Koltsovo;Replicating Viral Vector;x;;;; 170 | UW-Madison/FluGen/Bharat Biotech;Replicating Viral Vector;x;;;; 171 | Intravacc/ Wageningen Bioveterinary Research/Utrecht Univ.;Replicating Viral Vector;x;;;; 172 | The Lancaster University, UK;Replicating Viral Vector;x;;;; 173 | Providence Therapeutics;RNA;x;;;; 174 | Cell Tech Pharmed;RNA;x;;;; 175 | ReNAP Co.;RNA;x;;;; 176 | Globe Biotech Ltd;RNA;x;;;; 177 | Infectious Disease Research Institute/ Amyris, Inc.;RNA;x;;;; 178 | Max-Planck-lnstitute of Colloids and Interfaces;RNA;x;;;; 179 | Gennova;RNA;x;;;; 180 | Selcuk University;RNA;x;;;; 181 | Translate Bio/Sanofi Pasteur;RNA;x;;;; 182 | CanSino Biologics/Precision NanoSystems;RNA;x;;;; 183 | Fudan University/ Shanghai JiaoTong University/RNACure Biopharma;RNA;x;;;; 184 | Fudan University/ Shanghai JiaoTong University/RNACure Biopharma;RNA;x;;;; 185 | Centro Nacional Biotecnologfa (CNB-CSIC), Spain;RNA;x;;;; 186 | University of Tokyo/ Daiichi-Sankyo;RNA;x;;;; 187 | BIOCAD;RNA;x;;;; 188 | RNAimmune, Inc.;RNA;x;;;; 189 | FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo;RNA;x;;;; 190 | China CDC/Tongji University/Stermina;RNA;x;;;; 191 | Chula Vaccine Research Center/University of Pennsylvania;RNA;x;;;; 192 | eTheRNA;RNA;x;;;; 193 | Greenlight Biosciences;RNA;x;;;; 194 | IDIBAPS-Hospital Clinic, Spain;RNA;x;;;; 195 | OSE immunotherapeutics;T-cell based;x;;;; 196 | Shiraz University;VLP;x;;;; 197 | Tampere University;VLP;x;;;; 198 | Max Planck Institute for Dynamics of Complex Technical Systems;VLP;x;;;; 199 | University of Manitoba;VLP;x;;;; 200 | Bezmialem Vakif University;VLP;x;;;; 201 | Middle East Technical University;VLP;x;;;; 202 | VBI Vaccines Inc.;VLP;x;;;; 203 | IrsiCaixa AIDS Research/IRTA-CReSA/Barcelona Supercomputing Centre/Grifols;VLP;x;;;; 204 | Mahidol University/The Government Pharmaceutical Organization (GPO)/Siriraj Hospital;VLP;x;;;; 205 | Navarrabiomed, Oncoimmunology group;VLP;x;;;; 206 | Saiba GmbH;VLP;x;;;; 207 | Imophoron Ltd and Bristol University's Max Planck Centre;VLP;x;;;; 208 | Doherty Institute;VLP;x;;;; 209 | OS 1 VAX;VLP;x;;;; 210 | ARTES Biotechnology;VLP;x;;;; 211 | Univ. of Sao Paulo;VLP;x;;;; --------------------------------------------------------------------------------